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Preparation of the tri-arabino di-mycolate fragment of mycobacterial 
arabinogalactan from defined synthetic mycolic acids  
Mohsin O. Mohammed1, Juma’a R Al Dulayymi and Mark S. Baird*  
 School of Chemistry, Bangor University, Bangor, Wales, LL57 2UW  
1. Introduction: 
Tuberculosis (TB) is one of the world’s deadliest diseases 
and is caused by Mycobacterium tuberculosis, which has a 
single known host (man) [1,2]. The air-borne nature of this 
bacterium makes the disease highly infectious, and the World 
Health Organization (WHO) has reported that one third of 
the world’s population is probably infected with latent TB, 
and that there is a new case every second [3]. The 
mycobacterial cell wall has a complex structure made up of 
lipids, glycolipids, polysaccharides and proteins [4]. There 
has been growing interest in the construction of Darabino-
oligosaccharides related to mycobacterial cell wall 
components, arabino-galactan, lipoarabinomannan and 
arabinomannan from M. tuberculosis [5]. The 
mycolylarabinogalactan (mAG) complex is the largest 
component structure and forms from cross bonding between 
both Darabinofuranosyl (Araf) and galactofuranosyl (Galf) 
with a long-chain α-alkyl-branched β-hydroxylated fatty 
acid, ‘mycolic acid’ (MA) [6]. The complex lipids and 
polysaccharides within the cell wall of M. tuberculosis are 
assumed to be the cause of its characteristic pathogenesis  
[7].      
Anderson and Geiger in 1937 reported the first extraction of 
arabino-mycolate from the cell wall of Mycobacterium bovis 
using organic solvent [8]. Azuma et al. reported the isolation 
of arabinose mycolate under acidic conditions [9]. The 
structure of the mycolyl-arabinogalactan complex of M. 
tuberculosis was reinterpreted using mass spectrometry and 
NMR spectroscopy [10,11]. Synthetic arabinofuranosyl 
oligosaccharides, including a branched pentasaccharide were 
reported in 1998 [12,13]. In 2005, the preparation of a tetra-
mycolylpentaarabinose (1) (Fig. 1) using a complex natural 
mixture of MAs was described [14]. However, only in 2010 
were structural studies of the composition of the arabinose 
mycolates of the cell wall of M. bovis reported [15]. Ishiwata 
et al. reported the synthesis of a series of mono- (3), di- and 
tetra-arabinomycolates (1) found at the terminal position of 
the cell wall skeleton of BCG from M. bovis, using natural 
MA mixtures extracted from cells. All of the compounds 
showed strong TNF-α inducing activity in vitro.  Such 
arabinose mycolates have also been reported to show anti-
cancer properties [6]. The mechanism of the activity of 
arabinomycolates is not clear [14].   
Although a methoxy trisaccharide of arabinofuranose 2 
(Fig. 1) has been prepared and used in an acylation 
reaction with fatty acids such as behenic acid, palmitic 
acid and butyric acid [16], there are no examples of the 
synthesis of arabinofuranose oligosaccharides esterified 
with structurally defined complete synthetic mycolic 
acids (MAs) which are the main components of the cell 
wall of M. tuberculosis [6]. MAs 4 are β-hydroxy fatty 
acids with a long α-alkyl side chain (Fig. 2) [17,18].   
 
Fig. 1: Structure of targets of mycoloyl-arabinans.  
 
Fig. 2: Generalised MA structure and arabinose building 
blocks 
MAs in M. tuberculosis have 80-90 carbons, compared to 
those from corynebacterium (30-36 carbons), Rhodococcus 
(34-38 carbons) and Nocardia (46-60 carbons) [19,20]. 
Natural mixtures extracted from mycobacteria consist of 
many individual MA containing a range of functional 
groups, X and Y, including cis- and trans-cyclopropanes, 
cis- and transalkenes, methoxy and keto fragments, and 
different chain lengths [21].  
The aim of this study was to synthesize a series of 
dimycolated triarabinoses (2), comprising single defined 
synthetic mycolic acids, in order that the selectivity of their 
immune stimulatory activity, e.g. in inducing Interleukin 6 
(IL-6) and tumor necrosis factor alpha (TNF-α), could be 
evaluated.    
2  
 
2. Results and Discussion 
2.1. Synthesis of Trisaccharides  
The target trisaccharide structure 2 has two α-glycosidic 
linkages, which can be assembled readily from known building 
blocks, donor 5 [22] and acceptor 6 [23]. The route to the 2,3-
O-benzoyl-protected thioglycosyl donor 5 was slightly modified 
compared to the literature method (Scheme 1) [22]. D-(-)-
Arabinose was treated with HCl, freshly prepared by addition of 
acetyl chloride to anhydrous methanol at 0 ºC. Work up with 
pyridine rather than ammonium carbonate [24], gave methyl-α, 
β-D-Araf, 7 (R = H), with predominant formation of the α-
anomer (α/β-D, 3:2) [25,26]. Rather than esterifying with 
benzoate, the mixture was directly esterified to give triacetate 7 
(R = Ac) [22]. Condensation of this with p-thiotoluene in the 
presence of boron trifluoride etherate afforded 8 (R = Ac), which 
on reaction with NaOCH3 in methanol afforded thioglycoside 
triol 8 (R = H).  Protection of the primary alcohol as a silyl ether 
followed by benzoylation of the secondary alcohols gave 5.  
 
Scheme 1. Reagents and conditions: (a) Ac2O, pyridine, 0 ºC, 7 (R = Ac) 
80%; (b) TolSH (1.2 equiv.), BF3.Et2O (5.1 equiv.), CH2Cl2, 0 ºC/RT, 8 h, 8 
(R = Ac), 65%, (c) NaOCH3 (5 equiv.), CH3OH, RT, 3 h, 8 (R = H), 90%; (d) 
t-BuPh2SiCl (1.5 equiv), imidazole, DMF, 0 ºC/RT, 16 h, 82%; (e) BzCl (4.6 
equiv.), pyridine, 0 ºC/RT, 2 h, 83%.  
The initial step in the synthetic route to acceptor 6 [23], the 
separation of the two anomers of 7 (R = H), was carried out using 
two methods (Supplementary data, Schemes 1 and 2).   
Liu et al. [16] have reported the coupling of the monosaccharide 
building blocks to prepare the trisaccharide through the reaction 
of a 2-O-benzylated glycosyl acceptor and thioglycoside 5 using 
silver trifluoromethane sulfonate and Niodosuccinimide in dry 
CH2Cl2. In the present work, the benzoylated glycosyl acceptor 
6 and thioglycoside 5 were reacted under the reported conditions 
(Scheme 2). Trisaccharide 9a was obtained as a single 
stereoisomer in 87% yield, which is similar to that reported for 
the benzyl compound [16]. The product showed the expected 
three acetal signals in the proton NMR spectrum, two broad 
singlets at δ  
5.10 and 5.33, for the newly formed α-glycosidic links, and a 
third singlet at 5.56; these correlated by HSQC with three signals 
in the carbon spectrum for the glycosidic links at δ 107.0, 106.0 
and 105.3 respectively.  Compound 9a was deprotected with 
sodium methoxide to give 9b as a thick oil in 81% yield. This 
was benzylated to protect the five secondary hydroxyl groups 
using benzyl bromide and sodium hydride in dry DMF to give 
9c. Desilylation of the two primary hydroxyl groups gave 10a. 
Direct esterification of the primary hydroxyl group of Araf with 
a carboxyl group in natural mycolic acid mixtures has been 
achieved in a low yield (30%) [14], while activating the sugar as 
a tosylate raised the yield to 79%. Therefore, the two hydroxyl 
groups in compound 10a were tosylated using  p-toluenesulfonyl 
chloride in dry pyridine in the presence of  catalytic 4-
dimethylaminopyridine to afford the tosylate 10b (Scheme 2).  
 
Scheme 2. Reagents and conditions: (a) NIS, AgOTf, (9a, 87%); (b) 
NaOCH3 (cat.), CH3OH, rt, 2 h, (9b, 86%); (C) NaH, BnBr, DMF, 0 
ºC/rt 16 h, (9c, 79%); (d) TBAF, THF, 0 ºC/rt, 16 h (10a 77%); (e) TsCl, 
pyridine, DMAP, CH2Cl2 at 0 ºC (10b, 74%).   
The next step was the coupling of trisaccharide 10b with the 
structurally defined synthetic mycolic acids, which had 
been prepared earlier [27-29]. Firstly, a model tri-arabino-
di mycolate was prepared by coupling tosylate 10b with 
palmitic acid through the alkylative esterification strategy 
using cesium hydrogen carbonate in dry DMF: THF at 70 
ºC for four days [14], to give compound 11a, which was 
then debenzylated to give compound 12a (Scheme 3). The 
synthesis of this glycolipid has been reported using a 
different method. Data obtained for 12a was identical to that 
reported [16].  
A series of triarabino-dimycolates were then prepared 
according to the above procedure; the structures of the 
mycolic acid moieties, including α-, methoxy- and keto-
classes are shown in Scheme 3. In each case, the products 
the proton NMR spectra included the expected three 
characteristic broad single-hydrogen singlets for the acetal 
hydrogens in the region δ 4.9 – 5.2.  
 
Scheme 3. Reagents and conditions: (i) CsHCO3, THF-DMF, 4 days, 
70 ºC; (ii) Pd(OH)2, H2, CH2Cl2-MeOH, RT, overnight.  
  
2.2. IL-6 and TNF-α secretion assays with the synthesized 
compounds   
 Ishiwata et al. reported the synthesis of a series of mono-, di- 
and tetra-arabinomycolates found in the terminal position of the 
cell-wall skeleton of bacillus calmette Guerin from M. bovis, by 
using natural mycolic acid mixtures extracted from the cell wall 
and showed they differentially induce TNF- α secretion in a 
murine macrophage cell line, some at levels similar to trehalose 
dimycolate (TDM) [14]. Arabinomycolates obtained by acid 
hydrolysis from the originally prepared CWS (SMP-105) of M. 
bovis BCG Tokyo 172, consisting mainly of mono-arabinose 
mono-mycolate, pentaarabinose tetra-mycolate and hexa-
arabinose tetra-mycolate fractions, significantly induced TNF-α 
production with an intensity comparable to that of cell-wall 
skeleton, a potent adjuvant, and enhanced delayed type per 
sensitivity reactions against inactivated tumour cells. The 
induced TNF-α production was completely dependent on TLR2 
and MyD88 pathways [6]. To provide an initial evaluation of the 
activities of synthesised tri-arabino di-mycolates reported here 
(12c and 12f) as immune potentiators, secretion inducing assays 
for IL6 and TNF-α, cytokines involved in inflammation, were 
conducted, in comparison with TDM and synthetic 
monoarabino mono-mycolates [30]. Surprisingly, neither 
compound was strongly stimulatory in either assay when 
compared to synthetic TDMs, trehalose monomycolates or 
arabinose mycolates [31, 32]. Further work to evaluate the 
biological effects of these molecules is under way.  
3. Experimental Section 
For general experimental detail, see Supplementary Information. 
Unless otherwise stated, all products were single components by 
TLC and by proton and carbon NMR.  
3.1: Methyl 2,3-di-O-benzyl-5-O-p-toluenesulfonyl-α-
Darabinofuranosyl-(1→3)-[2,3-di-O-benzyl-5-O-p-toluene- 
sulfonyl-α-D-arabinofuranosyl-(1→5)]-2-O-benzyl-α-D- Araf  
10b 
(a) Molecular sieves 4 Å (6.6 g) were added to a stirred solution 
of the acceptor 6 (0.9 g, 3.3 mmol) and the donor 5 (6.0 g, 8.5 mmol) 
in dry CH2Cl2 (30 mL) at r.t. under a nitrogen atmosphere. The 
reaction mixture was stirred for 30 min. then cooled to -60 ºC and 
N-iodosuccinimide (2.09 g, 9.29 mmol) was added followed by the 
addition of AgOTf (0.36 g, 1.40 mmol). The mixture was stirred at 
the same temperature until the color became red/dark brown and 
TLC showed no starting material, then it was quenched by the 
addition of triethylamine (1 mL) until it turned yellow. The mixture 
was diluted with CH2Cl2 (100 mL) and filtered through celite and 
the solvent was evaporated under reduced pressure. Column 
chromatography on silica eluting with hexane/ethyl acetate (5:1) 
gave compound 9a as a thick oil (4.2 g, 87%) [Found (MALDI) 
(M+Na)+: 1447.6, C83H84NaO18Si2, requires: 1447.5], [ ]20D +16 (c 
0.1, CHCl3) which showed δH (400 MHz, CDCl3):  
8.07 (2H, d, J 7.9 Hz), 8.02 – 7.91 (8H, m), 7.70 – 7.62 (9H, m),  
7.59 – 7.41 (8H, m), 7.40 – 7.28 (18H, m), 5.64 (1H, d, J 4.5 Hz),  
5.61 (1H, d, J 4.2 Hz), 5.56 (1H, s), 5.57 (1H, s), 5.53 (1H, br. s),  
                                                             
1 .  
5.41 (1H, s), 5.32 (1H, br. s), 5.10 (1H, br. s), 4.49 – 4.35 (4H, 
m), 4.08 (1H, dd, J 11.3, 5.1 Hz), 3.97 (5H, m), 3.44 (3H, s), 
1.01 (9H, s), 0.98 (9H, s); δC (101 MHz, CDCl3): 165.5, 165.4, 
165.2,  
165.1, 135.63, 135.6, 135.5, 133.3, 133.2, 133.15, 133.1, 133.0, 
129.96, 129.9, 129.8, 129.78, 129.7, 129.6, 129.4, 129.3, 129.2, 
129.1, 128.4, 128.31, 128.3, 128.2, 127.6, 107.0, 106.0, 105.3, 
84.0, 83.4, 82.5, 82.0, 81.8, 81.6, 80.6, 77.2, 77.1, 66.1, 63.5, 
63.3,  
54.7, 26.7, 26.6, 19.3, 19.2; νmax: 3069, 3010, 2929, 2859, 1724, 
1602, 1451, 1070, 708 cm-1.  
(b) A solution of sodium methoxide (2 mL, 1 M, in 
methanol) was added to a stirred solution of 9a (0.20 g, 0.14 
mmol) in dry MeOH : CH2Cl2 (1:1, 5 mL) at r.t. until a pH of 
11 was obtained. The mixture was stirred at r.t. for 2 h then the 
solvent was evaporated under reduced pressure to give an oil. 
The residue was purified by column chromatography on silica 
eluting with CHCl3:MeOH (5:2) to give  9b compound as a 
thick oil  (0.1 g, 83%) [Found  
(MALDI) (M+Na)+: 927.1, C48H64NaO13Si2, requires: 927.3], [ ] 
22
D +50 (c 0.10, CHCl3) which showed δH (400 MHz, CDCl3 + few 
drops CD3OD): 7.49 – 7.34 (20H, m), 5.19 (1H, s), 5.14 (1H, s), 
4.86 (1H, s), 4.25 – 4.20 (2H, m), 4.18 (1H, br. d, J 1.8 Hz), 4.12 
(2H, br. d, J 3.8 Hz), 4.05 – 4.02 (4H, m), 4.01 – 3.95 (2H, m), 3.80 
(1H, dd, J 11.4, 2.3 Hz), 3.77 – 3.73 (2H, m), 3.70 (2H, br. d, J 11.3 
Hz), 3.34 (3H, s), 3.01 – 2.70 (4H, m), 1.10 – 0.99 (18H, m); δC 
(101 MHz, CDCl3 + few drops CD3OD): 135.7, 135.6, 135.5, 
129.5, 128.3, 128.0, 127.9, 127.8, 109.1, 108.6, 108.4,  
88.0, 87.4, 83.8, 82.4, 79.3, 78.9, 78.4, 77.8, 77.7, 66.1, 64.0,  
63.85, 54.8, 26.7, 26.6; νmax: 3445, 3010, 2928, 2860, 1494, 
1050, 824 cm-1.    
(c) Compound 9b (0.2 g, 0.2 mmol) in dry DMF:THF(1:1) 
(4 mL) was added dropwise (1 drop each 10 second) to a stirred 
suspension of NaH (0.1 g, 8.3 mmol) (60% w/w, dispersion in 
mineral oil, washed with petrol three times) at r.t. under 
nitrogen. The mixture was stirred for 30 min then benzyl 
bromide (0.1 mL, 0.8 mmol) in dry DMF (1 mL) was added, 
stirred at r.t. for 16 h, then quenched by slow addition of 
methanol (3 mL), and water (10 mL). The organic layer was 
separated and the aqueous layer was re-extracted with ethyl 
acetate (2×50 mL). The combined organic layers were washed 
with water (20 mL) and brine (20 mL), dried and the solvent 
evaporated under reduced pressure. Column chromatography 
on silica eluting with petrol/ethyl acetate (5:1) gave the title 
compound as a thick oil (0.23 g, 77%) [Found (MALDI) 
(M+Na)+: 1377.0, C83H94NaO13Si2, requires: 1377.6], [ ]22D 
+40 (c 0.1, CHCl3) which showed δH (400 MHz, CDCl3): 7.66 
– 7.51  (7H, m), 7.42 – 7.17 (38H, m), 5.19 (1H, s),  
5.17 (1H, s), 4.94 (1H, s), 4.59 – 4.37 (10H, m), 4.28 (1H, dd, 
J 6.3, 2.3 Hz), 4.22 – 4.14 (2H, m), 4.14 – 4.03 (5H, m), 4.03 
– 3.95  
(2H, m), 3.86 – 3.74 (5H, m), 3.37 (3H, s), 1.03 (18H, s); δC 
(101  
MHz, CDCl3): 135.7, 135.65, 135.62, 135.6, 129.6, 129.54, 
129.51, 128.5, 128.4, 128.35, 128.34, 128.3, 128.22, 128.2, 
127.9, 127.8, 127.79, 127.75, 127.73, 127.66, 127.63, 127.6, 
127.56, 127.53, 127.4, 127.35, 127.33, 127.3, 127.28, 107.2, 
(b) Palladium (II) hydroxide on activated charcoal (20%  
Pd(OH)2-C, 12 mg, 0.3 fold by weight) was added to a stirred  
4  
 
106.5, 105.4, 88.5, 88.3, 88.0, 83.1, 82.8, 82.3, 81.8, 81.2, 80.4, 
72.0, 71.9, 71.73, 71.7, 71.6, 66.2, 63.5, 63.3, 54.7, 26.8, 26.7; νmax: 
3466, 3050, 3017, 2958, 2930, 2858, 1493, 1112, 701 cm-1.  
(d) Tetrabutylammonium fluoride (0.3 mL, 0.3 mmol, 1 M) was 
added dropwise to a stirred solution of 9c (0.2 g, 0.147 mmol) in 
dry THF (10 mL) at 0 ºC under nitrogen atmosphere. The mixture 
was allowed to reach r.t. and stirred for 16 h then the solvent was 
evaporated under reduced pressure to give an oil which was purified 
by column chromatography on silica eluting with hexane/ethyl 
acetate (1:1) to give  compound 10a as a colourless thick oil (0.1 g, 
77%) [Found (MALDI) (M+Na)+ : 901.3, C51H58NaO13, requires : 
901.3], [ ] 20D +90 (c 0.1, CHCl3), which showed δH (400 MHz, 
CDCl3): 7.38 – 7.21 (25H, m), 5.16 (1H, s), 5.12 (1H, d, J 1.2 Hz), 
4.96 (1H, d, J 1.2 Hz), 4.61 – 4.42 (9H,m), 4.38 (1H, d, J 12.0 Hz), 
4.30 (1H, dd, J 7.4, 3.7 Hz), 4.25 (1H, ddd, J 6.3, 5.2, 2.9 Hz), 4.16 
– 4.07 (3H, m), 4.03 (1H, dd, J 3.7, 1.2 Hz), 4.01 (1H, dd, J 3.7, 1.2 
Hz), 3.95 (1H, dd, J 11.6, 3.8 Hz), 3.91 (1H, dd, J 6.6, 2.9 Hz), 3.85 
– 3.71 (4H, m), 3.66 (1H, dd, J 12.2, 5.2 Hz), 3.59 (1H, dd, J 12.2, 
5.8 Hz), 3.40 (3H, s), 2.84 (1H, br. s), 2.48 (1H, br. s); δC (101 MHz, 
CDCl3): 137.7,  
137.6, 137.4, 137.3, 137.2, 128.5, 128.44, 128.43, 128.4, 128.38, 
127.96, 127.94, 127.9, 127.87, 127.83, 127.8, 127.71, 106.9, 106.2, 
105.8, 88.7, 88.2, 87.5, 83.0, 82.9, 82.3, 81.9, 80.9, 79.7, 72.3, 72.2, 
72.0, 71.9, 71.8, 64.9, 62.8, 62.7, 54.9; νmax: 3467, 3050, 3017, 
2926, 2861, 1609, 1494, 1050, 824 cm-1.   
(e) 4-Toluenesulfonyl chloride (2.82 g, 14.7 mmol) was 
added to a stirred solution of 10a (1.30 g, 1.47 mmol), pyridine 
(1.17 g, 1.19 mL, 14.7 mmol) and DMAP (catalytic amount) in 
dry  
CH2Cl2 (10 mL) at 0 ºC under nitrogen. The mixture was 
allowed to reach r.t. and stirred for 16 h, then diluted with ethyl 
acetate (100 mL) and water (50 mL), the organic layer was 
separated and the aqueous layer was re-extracted with ethyl 
acetate (3×50 mL). The combined organic layers were washed 
with water (50 mL) and brine (50 mL), dried. The solvent was 
evaporated under reduced pressure to give an oil; column 
chromatography on silica eluting with hexane/ethyl acetate  
(1:1) afforded the title compound as a colorless thick oil 10b  
(1.3  g,  74%)  [Found  (MALDI)  (M+Na)+:  1209.2,  
C65H70NaO17S2, requires: 1209.3], [ ]
22
D +71 (c 0.10, CHCl3) which 
showed δH (400 MHz, CDCl3): 7.7 (2H, d, J 8.3 Hz),  
7.8 (2H, d, J 8.4 Hz), 7.37 – 7.23 (29H, m), 5.09 (1H, br. s), 5.08 
(1H, br. s), 4.93 (1H, s), 4.61 – 4.42 (9H, m), 4.35 (1H, d, J 12.0 
Hz), 4.30 – 4.24 (1H, m), 4.22 – 4.10 (6H, m), 4.10 – 4.05 (2H, 
m), 4.0 (1H, dd, J 3.3, 1.2 Hz), 3.96 (1H, dd, J 3.1, 
1.0 Hz), 3.87 (2H, dd, J 6.1, 3.1 Hz), 3.84 (1H, dd, J 12.0, 4.0 
Hz), 3.69 (1H, dd, J 12.0, 2.5 Hz), 3.38 (3H, s), 2.38 (3H, s), 2.4 
(3H, s); δC (101 MHz, CDCl3): 144.8, 144.7, 137.5, 137.4, 137.3, 
137.2, 137.1, 132.7, 132.6, 129.8, 129.7, 128.4, 128.38, 128.35, 
128.33, 128.3, 128.0, 127.93, 127.9, 127.85, 127.82, 127.8, 
127.7, 127.69, 127.67, 106.9, 106.4, 105.5, 88.0, 87.6,  
87.4, 82.8, 82.7, 80.5, 80.4, 79.0, 78.7, 72.2, 72.0, 71.8, 71.81,  
71.7, 68.7, 68.6, 65.7, 54.8, 21.5; νmax: 3088, 3064, 3031, 2924, 
2862, 1598, 1454, 1177, 738 cm-1.  
3.2: Methyl5-O-[(2R)-2-(1-hydroxy-18-[(1S,2R)-2-[(17S, 18S) 17-
methoxy-18-methylhexatriacontyl) cyclopropyl]octadecyl]- 
hexacosanoate)]-α-D-arabinofuranosyl-(1→3)-5-O-[(2R)-2-
(1hydroxy-18-[(1S,2R)-2-[(17S,18S)-17-methoxy-18-
methylhexatriacontyl)cyclopropyl]octadecyl]hexacosanoate)]-
α-D-arabinofuranosyl-(1→5)]-α-D-Araf 12b 
(a) Cesium hydrogencarbonate (0.065 g, 0.335 mmol) was 
added to a stirred solution of 10b (0.040 g, 0.033 mmol) and 
(2R)-2-{1-hydroxy-18-[(1S,2R)-2-[(17S,18S)-17-
methoxy18-
methylhexatriacontyl]cyclopropyl]octadecyl}hexacosanoic 
acid [28] (0.092 g, 0.073 mmol) in dry DMF : THF (1:5, 3 
mL) at r.t. under a nitrogen atmosphere. The mixture was 
stirred at 70 ºC for 4 days, then worked up and purified as 
before to afford 11b as a colourless thick oil (0.051 g, 45%)  
[Found (MALDI) (M+Na)+: 3371.9, C221H390NaO19, 
requires: 3371.9], [ ]23D +35 (c 0.1, CHCl3) which showed 
δH (400 MHz, CDCl3): 7.37 – 7.23 (25H, m), 5.18 (1H, br. 
s), 5.13 (1H, br.  
s), 4.91 (1H, br. s), 4.49 – 4.37 (9H, m), 4.34 (1H, d, J 11.7 
Hz), 4.32 – 4.24 (6H, m), 4.18 (1H, ddd, J 9.7, 6.3, 3.0 Hz), 
4.11 (1H, dd, J 4.4, 2.7 Hz), 4.08 (1H, br. d, J 2.9 Hz), 4.00 
(1H, dd, J 2.9, 0.6 Hz), 3.96 (1H, br. d, J 2.3 Hz), 3.93 (1H, 
dd, J 7.8, 3.9 Hz), 3.88 – 3.78 (2H, m), 3.76 (1H, dd, J 11.4, 
1.8 Hz), 3.67 – 3.57 (2H, m), 3.37 (3H, s), 3.35 (6H, s), 2.99  
– 2.93 (2H, m), 2.67 (1H, d, J 6.1 Hz), 2.65 (1H, d, J 6.5 Hz), 
2.41 (2H, dt, J 9.0, 5.8 Hz), 1.68 – 1.03 (294H, m), 0.89 
(12H, t, J 6.8 Hz), 0.86 (6H, d, J 6.9 Hz), 0.71 – 0.61 (4H, 
m), 0.57 (2H, dt, J 7.6, 4.0 Hz), -0.33 (2H, br. q, J 5.1 Hz); 
δC (101 MHz, CDCl3): 175.1, 175.0, 137.7, 137.6, 137.5, 
137.4, 137.2, 128.5, 128.41, 128.4, 127.95, 127.9, 127.8, 
127.73, 127.7, 107.0, 106.3, 105.5, 88.2, 87.9, 87.8, 85.4, 
83.7, 80.6, 80.4,  
79.3, 79.1, 72.3, 72.2, 72.1, 71.98, 71.8, 65.6, 63.0, 57.7, 54.8,  
51.9, 51.7, 35.3, 32.4, 31.9, 30.5, 30.2, 29.97, 29.9, 29.7, 
29.66, 29.5, 29.4, 28.7, 27.6, 26.2, 22.7, 15.8, 14.9, 14.1, 
10.9; νmax: 3517, 3063, 3031, 2922, 2852, 1736, 1466, 1101, 
757 cmsolution of compound 11b (0.042 g, 0.014 mmol) in 
dry CH2Cl2 : MeOH (1:1, 2 mL) at r.t. under a hydrogen. The 
mixture was stirred for 16 h, then filtered and the solvent was 
evaporated under reduced pressure; column chromatography 
on silica eluting with CHCl3:MeOH (5:1)  gave the title 
compound 12b as a thick oil (0.03 g, 82%) [Found (M+Na)+: 
2921.8, C186H360NaO19, requires: 2921.7], [ ]
20
D +21 (c 0.10,  
CHCl3) which showed δH (500 MHz, CDCl3 + few drops 
CD3OD): 4.98 (1H, br. s), 4.95 (1H, br. s), 4.77 (1H, br. s),  
4.40 (1H, dd, J 11.8, 4.3 Hz), 4.33 (1H, dd, J 11.6, 4.5 Hz),  
4.24 (1H, dd, J 11.6, 4.7 Hz), 4.15 (1H, dd, J 11.6, 4.3 Hz),  
4.13 – 4.07 (2H, m), 4.07 – 3.94 (5H, m), 3.94 – 3.80 (3H, 
m), 3.67 – 3.55 (3H, m), 3.36 (3H, s), 3.32 (6H, s), 2.96 – 
2.90 (2H, m), 2.37 – 2.30 (2H, m), 1.61 – 0.97 (301H, m), 
0.82 (12H, t, J 7.0 Hz), 0.79 (6H, d, J 6.9 Hz), 0.64 – 0.55 
(4H, m),  
0.50 (2H, dt, J 8.0, 4.0 Hz), -0.39 (2H, br. q, J 5.1 Hz); δC 
(126 MHz, CDCl3 + few drops CD3OD): 175.1, 175.0, 
109.1, 107.9, 107.2, 85.5, 83.0, 82.4, 81.8, 81.0, 79.8, 77.9, 
72.5, 72.45,  
65.9, 63.4, 63.1, 57.5, 54.8, 52.8, 50.0, 35.2, 34.8, 34.7, 
32.2,  
31.8, 30.3, 30.1, 29.82, 29.8, 29.62, 29.6, 29.56, 29.5, 29.4,  
29.3, 29.2, 29.1, 28.6, 27.4, 27.3, 25.96, 25.2, 25.2, 22.5, 
15.6,  
  
14.7, 13.9, 10.7; νmax: 3401, 2919, 2851, 1733, 1467, 1099, 720 
cm-1.   
3.3:  Methyl  5-O-(2-[(R)-1-hydroxy-18-[(1R,2S)-2-[(17S, 
18S)-17-methoxy-18-
methylhexatriacontyl]cyclopropyl]octadecyl]-tetracosanoate)-
α-D-arabino-furanosyl-(1→3)[5-O-(2-[(R)-1-hydroxy-18-
[(1R,2S)-2-[(17S,18S)-17methoxy-18-methyl-
hexatriacontyl]cyclopropyl]octadecyl]tetracosanoate)-α-D-
arabinofuranos-yl-(1→5)]-α-D-Araf  
12c 
(a) Cesium hydrogencarbonate (0.081 g, 0.417 mmol) was 
added to a stirred solution of 10b (0.050 g, 0.042 mmol) and 
(2R)-2-{(1R)-1-hydroxy-18-[(2S)-2-[(17S,18S)-17-methoxy18-
ethylhexatriacontyl]cyclopropyl]octadecyl}tetracosanoic acid  
[33] (0.113 g, 0.092 mmol) in dry DMF : THF (1:5, 6 mL) at r.t. 
under nitrogen. The mixture was stirred at 70 ºC for 4 days, then 
work up and purification as before gave 11c as a colourless thick 
oil (50 mg, 36%) [Found (M+Na)+: 3315.8808, C217H382NaO19, 
requires: 3315.8818], [ ]23D +40 (c  
0.1, CHCl3) which showed δH (400 MHz, CDCl3): 7.39 – 7.22 
(25H, m), 5.18 (1H, s), 5.13 (1H, s), 4.91 (1H, s), 4.61 – 4.42 
(9H, m), 4.38 (1H, d, J 12.0 Hz), 4.30 – 4.23 (6H, m), 4.22 – 
4.16 (1H, m), 4.14 – 4.05 (2H, m), 4.03 (1H, dd, J 3.2, 1.0 Hz), 
3.98 (1H, dd, J 3.2, 1.0 Hz), 3.95 (1H, dd, J 12.0, 4.6 Hz), 3.86  
– 3.80 (2H, m), 3.78 (1H, dd, J 12.0, 2.3 Hz), 3.67 – 3.57 (2H, 
m), 3.37 (3H, s), 3.35 (6H, s), 3.01 – 2.92 (2H, m), 2.67 (2H, br. 
s), 2.45 – 2.37 (2H, m), 1.72 – 1.07 (285 H, m), 0.89 (12H, t, J 
6.8 Hz), 0.86 (6H, d, J 6.9 Hz), 0.71 – 0.60 (4H, m), 0.61  
– 0.53 (2H, dt, J 7.6, 4.0 Hz ), -0.32 (2H, br. q, J 5.2 Hz); δC  
(101 MHz, CDCl3): 175.1, 174.9, 137.6, 137.51, 137.5, 137.4, 
137.2, 128.45, 128.41, 128.4, 128.38, 128.37, 127.9, 127.85, 
127.8, 127.74, 127.7, 107.0, 106.3, 105.5, 88.2, 87.9, 87.8,  
85.4, 83.7, 83.6, 80.6, 80.4, 79.3, 79.1, 72.3, 72.2, 72.1, 72.0,  
71.9, 71.7, 65.5, 63.0, 57.7, 54.8, 51.8, 51.7, 35.3, 32.4, 31.9,  
30.5, 30.2, 29.98, 29.9, 29.7, 29.6, 29.5, 29.4, 28.7, 27.6, 27.4,  
26.2, 22.7, 15.7, 14.8, 14.1, 10.9; νmax: 3436,  2920, 2851, 1733, 
1734, 1174, 734 cm-1.  
(b) Palladium (II) hydroxide on activated charcoal (20% 
Pd(OH)2-C, 0.01 g, 0.30 fold by weight) was added to a stirred 
solution of compound 11c (0.037 g, 0.010 mmol) in dry CH2Cl2 
: MeOH (1:1, 2 mL) at r.t. under hydrogen. After 16 h, work up 
and purification as before gave the title compound 12c as a white 
oil (21 mg, 65%) [Found (M+Na)+: 2865.6424, C182H352NaO19, 
requires: 2865.6470], [ ]16D +24 (c 0.1, CHCl3) which showed 
δH (400 MHz, CDCl3 + few drops CD3OD):  
5.02 (1H, d, J 1.5 Hz), 4.98 (1H, br. s), 4.80 (1H, br. s), 4.46 (1H, 
dd, J 11.7, 4.3 Hz), 4.37 (1H, dd, J 11.6, 4.8 Hz), 4.27 (1H, dd, 
J 11.7, 4.9 Hz), 4.16 (1H, dd, J 12.0, 4.8 Hz), 4.14 – 4.08 (2H, 
m), 4.08 – 3.99 (5H, m), 3.95 – 3.87 (3H, m), 3.62  
– 3.52 (3H, m), 3.35 (3H, s), 3.31 (6H, s), 2.94 – 2.85 (2H, m), 
2.44 – 2.34 (2H, m), 1.37 – 1.13 (292H, m), 0.85 (12H, t, J 6.8 Hz), 
0.82 (6H, d, J 6.9 Hz), 0.66 – 0.57 (4H, m), 0.56 – 0.49  
(2H, dt, J 7.6, 4.0 Hz ), -0.37 (2H, br. q, J 5.2 Hz); δC (101 MHz, 
CDCl3 + few drops CD3OD): 175.2, 175.0, 109.1, 107.9, 107.2, 
85.5, 82.9, 82.5, 82.0, 81.8, 81.0, 80.9, 79.7, 78.0, 72.5,  
66.9, 65.9, 63.1, 57.6, 54.8, 52.8, 35.2, 32.3, 31.8, 30.4, 30.1,  
29.8, 29.7, 29.66, 29.6, 29.5, 29.3, 29.2, 28.6, 27.4, 26.0, 22.5,  
15.7, 14.7, 14.0, 10.8; νmax: 3412,  2919, 2850, 1731, 1466, 1099, 
720 cm-1.  
3.4: Methyl 5-O-(2-[(R)-1-hydroxy-12-{(1R,2S)-2-(14-[(1R, 
2S)-2-eicosylcyclopropyl]tetradecyl]cyclopropyl}dodecyl)- 
hexacosanoate)-α-D-arabinofuranosyl-(1→3)-[5-O-(2-
[(R)1-hydroxy-12-{(1R,2S)-2-(14-[(1R,2S)-2-eicosyl-
cyclopropyl]tetradecyl]cyclopropyl}dodecyl)hexacosanoate
)-α-Darabinofuranosyl-(1→5)]-α-D-Araf 12d  
(a) Cesium hydrogencarbonate (0.089 g, 0.458 mmol) 
was added to a stirred solution of 10b (0.055 g, 0.046 mmol) 
and (2R)-2-{(1R)-1-hydroxy-12-[(1R)-2-[14-[(2S)-2-
eicosylcyclopropyl]tetradecyl]cyclopropyl]dodecyl}hexaco
sanoic acid [27] (0.115 g, 0.101 mmol) in dry DMF : THF 
(1:5, 6 mL) at r.t. under hydrogen. The mixture was stirred 
at 70 ºC for 4 days then work up and purification as before 
afforded 11d as a colourless oil (56 mg, 18%) [Found 
(M+Na)+ : 3139.7057, C207H358NaO17, requires: 3139.7041], 
[ ]23D +72 (c  
0.1, CHCl3) which showed δH (400 MHz, CDCl3): 7.37 – 7.22 
(25H, m), 5.18 (1H, br. s), 5.14 (1H, br. s), 4.92 (1H, br. s),  
4.61 – 4.43 (9H, m), 4.35 (1H, d, J 12.0 Hz), 4.32 – 4.25 (6H, 
m), 4.22 – 4.16 (1H, m), 4.09 – 4.03 (2H, m), 4.01 (1H, dd, J  
3.0, 1.0 Hz), 3.97 (1H, dd, J 3.0, 1.0 Hz), 3.92 (1H, dd, J 12.0,  
7.5 Hz), 3.88 – 3.80 (2H, m), 3.77 (1H, dd, J 12.0, 2.2 Hz),  
3.62 – 3.55 (2H, m), 3.38 (3H, s), 2.68 – 2.52 (2H, m), 2.46 –  
2.36 (2H, m), 1.70 – 1.06 (268H, m), 0.89 (12H, t, J 6.8 Hz), 
0.71 – 0.62 (8H, m), 0.60 – 0.54 (4H, dt, J 7.6, 4.0 Hz), -0.32  
(4H, br. q, J 5.2 Hz); δC (101 MHz, CDCl3): 175.1, 174.9, 
137.6, 137.51, 137.5, 137.4, 137.2, 128.5, 128.4, 128.38, 
128.37, 128.0, 127.9, 127.8, 127.71, 127.7, 107.0, 106.3, 
105.5, 88.2, 87.9, 87.8, 83.6, 80.6, 80.4, 79.3, 79.1, 72.3, 
72.2,  
72.0, 71.9, 71.7, 65.6, 63.0, 54.8, 51.85, 51.7, 35.4, 35.2, 31.9, 
30.2, 29.8, 29.75, 29.7, 29.6, 29.5, 29.4, 29.2, 28.7, 27.5, 27.4,  
25.7, 22.7, 18.5, 18.3, 15.7, 14.1, 10.9; νmax: 3584, 3064, 3032, 
2918, 2850, 1733, 1455, 1018, 732  cm-1.  
(b) Palladium (II) hydroxide on activated charcoal 
(20% Pd(OH)2-C, 6.6 mg, 0.30 fold by weight) was added to 
a stirred solution of compound 11d (0.030 g, 0.009 mmol) in 
dry CH2Cl2 : MeOH (1:1, 2 mL) at r.t. under hydrogen. 
After16 h, work up and purification as before gave the title 
compound 12d as a colourless oil (17 mg, 64%) [Found 
(M+Na)+: 2689.4696, C172H328NaO17, requires: 2689.4694], 
[ ]16D +36 (c 0.1, CHCl3) which showed δH (400 MHz, 
CDCl3 + few drops CD3OD): 5.03 (1H, d, J 1.5 Hz), 4.99 
(1H, br. s), 4.81 (1H, br.  
s), 4.48 (1H, dd, J 11.9, 4.3 Hz), 4.39 (1H, dd, J 11.7, 4.7 
Hz), 4.28 (1H, dd, J 11.5, 4.8 Hz), 4.17 (1H, dd, J 11.4, 4.3 
Hz), 4.13 – 3.09 (2H, m), 4.06 – 3.98 (5H, m), 3.97 – 3.86 
(3H, m),  
3.69 – 3.58 (3H, m), 3.36 (3H, s), 2.51 – 2.42 (2H, m), 2.42 
–  
2.35 (2H, m), 1.70 – 1.00 (271H, m), 0.86 (12H, t, J 6.8 Hz), 
0.67 – 0.58 (8H, m), 0.57 – 0.50 (4H, dt, J 7.6, 4.0 Hz), -
0.36  
(4H, br. q, J 5.1 Hz); δC (101 MHz, CDCl3 + few drops 
CD3OD): 175.2, 175.0, 109.0, 107.8, 107.3, 83.1, 82.9, 
81.5,  
81.1, 80.0, 77.97, 72.99, 72.9, 65.7, 63.6, 63.2, 54.9, 52.8,  
52.7, 31.9, 30.3, 30.2, 29.8, 29.75, 29.7, 29.6, 29.5, 29.4, 
28.7,  
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27.4, 22.7, 15.8, 14.1, 10.9; νmax: v. br. 3400, 2919, 2851, 1732, 
1467, 1099, 760 cm-1.  
3.5: Methyl-5-O-(2-{(R)-1-hydroxy-12-[(1S,2R)-2-(14-[(1S, 
2R)-2-
eicosylcyclopropyl]tetradecyl)cyclopropyl]dodecyl}hexacosan
oate)-α-D-arabinofuran-osyl-(1→3)-[5-O-(2-{(R)1-hydroxy-
12-[(1S,2R)-2-(14-[(1S,2R)-2-icosylcycloprop-yl] tetradecyl)-
cyclopropyl]dodecyl}hexacosanoate)-α-Darabinofuranosyl-
(1→5)]-α-D-Araf 12e  
(a) Cesium hydrogencarbonate (0.081 g, 0.417 mmol) was 
added to a stirred solution 10b (0.050 g, 0.042 mmol) and 2{(R)-
1-hydroxy-12-[(1S,2R)-2-(14-[(1S,2R)-2-
eicosylcyclopropyl]tetradecyl)cyclopropyl]dodecyl}hexacosan
oic acid [27] (0.105 g, 0.092 mmol) in dry DMF : THF (1:5, 3 
mL) at r.t. under hydrogen. The mixture was stirred at 70 ºC for 
4 days, then work and purification as before gave a colourless 
oil, compound 11e (31 mg, 11%) [Found (MALDI) (M+Na)+: 
3139.7, C207H358NaO17 requires: 3139.7], [ ]
23
D +80 (c 0.1,  
CHCl3) which showed δH (400 MHz, CDCl3): 7.35 – 7.27 (25H, 
m), 5.18 (1H, br. s), 5.13 (1H, br. s), 4.91 (1H, br. s),  
4.61 – 4.39 (9H, m), 4.40 (1H, d, J 12.8 Hz), 4.35 (1H, dd, J  
9.4, 4.6 Hz), 4.32 – 4.23 (5H, m), 4.21 – 4.17 (1H, m), 4.11 –  
4.05 (2H, m), 4.00 (1H, br. d, J 2.7 Hz), 3.98 – 3.95 (1H, m),  
3.95 – 3.91 (1H, m), 3.90 – 3.85 (2H, m), 3.76 (1H, dd, J 11.7,  
2.2 Hz), 3.66 – 3.57 (2H, m), 3.37 (3H, s), 2.69 – 2.62 (2H, m), 
2.45 – 2.36 (2H, m), 1.64 – 1.07 (268H, m), 0.89 (12H, t, J 6.9 
Hz), 0.70 – 0.61 (8H, m), 0.56 (4H, dt, J 7.6, 4.0 Hz), - 
0.33 (4H, br. q, J 5.2 Hz); δC (101 MHz, CDCl3): 175.1, 175.0, 
137.7, 137.5, 137.4, 137.3, 137.2, 128.5, 128.4, 128.38, 128.37, 
127.95, 127.9, 127.8, 127.73, 127.7, 107.0, 106.3, 105.5, 88.2, 
87.9, 87.8, 83.6, 80.6, 79.2, 79.1, 72.3, 72.2, 72.1,  
72.0, 71.9, 71.7, 65.6, 63.0, 60.4, 54.8, 51.8, 51.7, 31.9, 30.2, 
29.72, 29.7, 29.6, 29.5, 29.4, 28.7, 22.6, 15.8, 14.1, 10.9; νmax: 
3524, 3035, 2918, 2850, 1735, 1466, 1018, 734 cm-1.  
(b) Palladium (II) hydroxide on activated charcoal (20% 
Pd(OH)2-C, 8.2 mg, 0.30 fold by weight) was added to a stirred 
solution of compound 11e (0.027 g, 0.008 mmol) in dry CH2Cl2 
: MeOH (1:1, 2 mL) at r.t. under hydrogen. After 16 h, work up 
and purification as before gave the title compound 12e as a 
colourless oil (23.1 mg, 97%) [Found (MALDI) (M+Na)+: 
2689.4, C172H328NaO17, requires: 2689.4], [ ]
20
D +40  
(c 0.1, CHCl3) which showed δH (400 MHz, CDCl3+ few drops 
CD3OD): 4.94 (1H, d, J 1.3 Hz), 4.92 (1H, br. s), 4.73 (1H, br.  
s), 4.35 (1H, dd, J 11.8, 4.7 Hz), 4.29 (1H, dd, J 11.5, 3.9 Hz),  
4.20 (1H, dd, J 11.5, 4.8 Hz), 4.13 (1H, dd, J 11.7, 4.8 Hz),  
4.09 – 4.02 (2H, m), 4.02 – 3.92 (5H, m), 3.89 – 3.77 (3H, m),  
3.61 – 3.49 (3H, m), 3.28 (3H, s), 2.38 – 2.29 (2H, m), 1.51 –  
0.94 (274H, m), 0.79 (12H, t, J 6.8 Hz), 0.61 – 0.52 (8H, m),  
0.47 (4H, dt, J 7.6, 4.0 Hz), -0.42 (4H, br. q, J 5.1 Hz); δC (101 
MHz, CDCl3 + few drops CD3OD): 175.1, 175.0, 109.0, 107.9, 
107.3, 82.9, 82.2, 81.8, 81.6, 81.0, 80.9, 79.7, 77.8, 77.5, 72.3,  
66.0, 63.4, 63.1, 54.7, 52.7, 49.6, 34.7, 31.7, 30.0, 29.9, 29.6,  
29.5, 29.4, 29.2, 29.1, 29.0, 28.5, 27.2, 22.4, 15.5, 13.8, 10.7,  
10.6; νmax: 3400, 2918, 2850, 1735, 1467, 1008 cm-1.   
3.6: Methyl5-O-{2-((1R)-1-hydroxy-16-[(1R,2S)-2-(20methyl-
19-oxo-octatriacontyl)cyclopropyl]hexadecyl)hexacosanoyl}-α-
D-arabinofuranosyl-(1→3)-[2,3-di-O-benzyl-5O-{2-(1R)-1-
hydroxy-16-[(1R,2S)-2-(20-methyl-19-
oxooctatriacontyl)cyclopropyl]hexadecyl)hexacosanoyl}-α-
Darabinofuranosyl-(1→5)]-α-D-Araf 12f  
(a) Cesium hydrogencarbonate (0.081 g, 0.417 mmol) was 
added to a stirred solution of 10b (0.050 g, 0.042 mmol) and 
(2R)-2-{(1R)-1-hydroxy-16-[(2S)-2-[20-methyl-19-oxo-
octatriacontyl]cyclopropyl]hexadecyl}hexacosanoic acid 
[29] (0.114 g, 0.092 mmol) in dry DMF : THF (1:5, 6 mL) 
at r.t. under nitrogen. The mixture was stirred at 70 ºC for 4 
days, then work up and purification as before gave 
compound 11f as a colourless thick oil (0.05 g, 36%) [Found 
(MALDI)  
(M+Na)+: 3339.7, C219H382NaO19, requires: 3339.8], [ ]
23
D +62  
(c 0.1, CHCl3) which showed δH (400 MHz, CDCl3): 7.34 – 7.25 
(25H, m), 5.18 (1H, br. s), 5.13 (1H, br. s), 4.91 (1H, br.  
s), 4.60 – 4.40 (9H, m), 4.34 (1 H, d, J 11.8 Hz), 4.32 – 4.24 
(4H, m), 4.18 (1H, dt, J 10.7, 3.5 Hz ), 4.11 (1H, dd, J 4.1, 
2.9 Hz), 4.08 (1H, br. d, J 3.0 Hz), 4.04 – 4.01 (1H, m), 4.00 
(1H, br. d, J 2.4 Hz), 3.96 – 3.94 (2H, m), 3.93 (1H, dd, J 7.4, 
4.4 Hz), 3.88 – 3.80 (2H, m), 3.76 (1H, dd, J 12.0, 2.0 Hz), 
3.70 – 3.55 (3H, m), 3.37 (3H, s), 2.67 (1H, br. s), 2.55 – 
2.34 (8H, m), 1.69 – 1.10 (288H, m), 1.06 (6H, d, J 6.9 Hz), 
0.89 (12H, t, J 6.8), 0.66 – 0.62 (4H, m), 0.61 – 0.51 (2H, dt, 
J 7.6, 4.0 Hz), -0.32 (2H, br. q, J 5.1 Hz); δC (101 MHz, 
CDCl3): 215.2, 175.1, 174.96, 137.7, 137.5, 137.4, 137.2, 
128.4, 128.41, 128.38, 128.36, 128.0, 127.9, 127.8, 127.73, 
127.7, 107.0, 106.3, 105.5, 88.2, 87.9, 87.85, 83.7, 80.6, 
80.4, 79.3, 79.1,  
72.3, 72.2, 72.1, 71.97, 71.8, 68.9, 65.6, 63.0, 54.8, 51.8, 51.7,  
50.9, 46.3, 41.1, 33.0, 32.1, 31.9, 30.2, 29.7, 29.66, 29.6, 29.5,  
29.49, 29.4, 29.36, 29.3, 29.2, 28.7, 27.4, 27.3, 25.7, 23.7,  
22.8, 22.7, 16.4, 15.7, 14.1, 10.9; νmax: 3522, 3066, 2919, 2851, 
1735, 1712, 1467, 1111, 756, 720 cm-1.   
(b) Palladium (II) hydroxide on activated charcoal (20% 
Pd(OH)2-C, 13.8 mg, 0.30 fold by weight) was added to a 
stirred solution of compound 11f (0.046 g, 0.013 mmol) in 
dry CH2Cl2 : MeOH (1:1, 2 mL) at r.t. under hydrogen. After 
16 h, work up and chromatography as before gave the title 
compound 12f as a colourless oil (26 mg, 65%) [Found  
(M+Na)+: 2889.6404, C184H352NaO19, requires: 2889.6470], 
[ ]23D +33 (c 0.1, CHCl3) which showed δH (400 MHz, 
CDCl3+ few drops CD3OD): 5.00 (1H, d, J 1.8 Hz), 4.96 
(1H, d, J 0.6 Hz), 4.79 (1H, br. s), 4.43 (1H, dd, J 12.2, 4.6 
Hz), 4.35 (1H, dd, J 12.2, 4.9 Hz), 4.26 (1H, dd, J 11.8, 5.0 
Hz), 4.16 (1H, dd, J 11.4, 4.2 Hz), 4.13 – 4.07 (2H, m), 4.04 
– 3.97 (5H, m), 3.94 – 3.84 (3H, m), 3.67 – 3.56 (4H, m), 
3.34 (3H, s), 3.11 (1H, d, J 7.4 Hz), 3.07 (1H, d, J 7.3 Hz), 
2.47 – 2.43 (3H, m), 2.41 – 2.3 (7H, including t at 2.38 with 
J 7.5 Hz), 1.63 – 1.10 (292H, m), 1.00 (6H, d, J 6.9 Hz), 0.84 
(12H, t, J 6.7 Hz), 0.65  
– 0.56 (4H, m), 0.51 (2H, dt, J 7.6, 4.0 Hz), -0.38 (2H, br. q, J 
5.1 Hz); δC (101 MHz, CDCl3 + few drops CD3OD): 216.3, 
175.1, 175.0, 109.1, 107.9, 107.3, 83.0, 82.3, 81.8, 81.7, 81.0,  
80.9, 79.7, 77.9, 72.4, 72.3, 65.97, 63.1, 60.4, 54.7, 52.7, 46.2,  
41.0, 34.7, 32.9, 31.7, 30.0, 29.5, 29.3, 29.2, 29.1, 28.5, 27.3, 
27.1, 25.5, 23.5, 22.5, 16.1, 15.6, 13.8, 10.7; νmax: 3393, 
2919, 2850, 1713, 1467, 1100, 720 cm-1.  
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